Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Traws Pharma, Inc.

NASDAQ: TRAW · Life Sciences · 3 alerts · CIK 1130598

Share price
$0.2600Close, Nov 16
Market cap
$4M
Shares outstanding
15.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Traws Pharma, Inc. filings on SEC EDGAR ↗

7:01 AM ET 8-K
Clinical Trial Data

Traws Pharma Clinical Trial Data

Traws Pharma announced final Phase 2a results for Ratutrelvir, showing symptom resolution comparable to PAXLOVID with no viral rebound and fewer treatment-related adverse events in COVID-19 patients. The company also completed a bridging study for Tivoxavir Marboxil (TXM), supporting its potential as a once-monthly influenza prophylactic agent.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.